Intestinal Failure Unit, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
General Surgery Unit, Stanley Dudrick's Memorial Hospital, Skawina, Poland.
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1198-1209. doi: 10.1002/jpen.1761. Epub 2020 Jan 27.
Use of catheter lock solutions (CLSs) as a strategy to prevent catheter-related bloodstream infections (CRBSIs) has been evaluated in recent clinical trials. Our aim was to identify the most effective CLS formulation in patients receiving home parenteral nutrition (HPN).
We conducted a systematic review and individual-patient data meta-analysis (IPDMA). Prospective randomized clinical trials in adult HPN patients using CLS were identified from PubMed, EMBASE, Web of Science, CINAHL, Cochrane library, and ClinicalTrials.gov. Primary outcome was the number of CRBSIs per 1000 catheter days for each CLS. Other outcomes included time to CRBSI and identification of patients with a higher risk for CRBSIs.
In total, 1107 studies were screened for eligibility, of which three studies comprising 162 HPN patients and 45,695 catheter days were included in the IPDMA. CRBSI rates were significantly decreased in patients using taurolidine (rate 0.13; 95% confidence interval [CI], 0.05-0.32) when compared with saline (rate 0.74; 95% CI, 0.31-1.74; P = .002) or heparin (rate 2.01; 95% CI, 1.03-3.91; P < .001). The cumulative proportion of CRBSI-free patients using taurolidine, saline, and heparin after 1 year was 88%, 56%, and 14%, respectively. Three risk factors for CRBSIs were identified: type of CLS, intestinal dysmotility as underlying condition, and use of central venous catheters.
Taurolidine was the most effective CLS formulation in HPN patients for the prevention of CRBSIs. We suggest discussing with patients the benefits and risks when starting taurolidine, especially in patients who are considered to have a higher risk for CRBSIs.
最近的临床试验评估了使用导管锁定溶液 (CLS) 作为预防导管相关血流感染 (CRBSI) 的策略。我们的目的是确定在接受家庭肠外营养 (HPN) 的患者中最有效的 CLS 配方。
我们进行了系统评价和个体患者数据荟萃分析 (IPDMA)。从 PubMed、EMBASE、Web of Science、CINAHL、Cochrane 图书馆和 ClinicalTrials.gov 中确定了正在使用 CLS 的成年 HPN 患者的前瞻性随机临床试验。主要结局是每个 CLS 每 1000 个导管日发生的 CRBSI 数量。其他结局包括 CRBSI 时间和确定 CRBSI 风险较高的患者。
共筛选了 1107 项研究以确定其是否符合入选标准,其中三项研究包括 162 名 HPN 患者和 45695 个导管日,纳入了 IPDMA。与生理盐水 (率 0.74;95%置信区间 [CI],0.31-1.74;P =.002) 或肝素 (率 2.01;95%CI,1.03-3.91;P<.001) 相比,使用牛磺胆酸钠的患者 CRBSI 发生率显著降低 (率 0.13;95%CI,0.05-0.32)。使用牛磺胆酸钠、生理盐水和肝素的患者在 1 年后无 CRBSI 的累积比例分别为 88%、56%和 14%。确定了三个 CRBSI 的危险因素:CLS 类型、潜在疾病的肠动力障碍和使用中心静脉导管。
牛磺胆酸钠是 HPN 患者预防 CRBSI 最有效的 CLS 配方。我们建议在开始使用牛磺胆酸钠时与患者讨论其益处和风险,特别是对于那些被认为 CRBSI 风险较高的患者。